Sign in

SLSN on Nasdaq

SOLESENCE, INC.

SOLESENCE, INC. is an American perfumes company, incorporated in Delaware, listed on Nasdaq (SLSN).1 It is headquartered in Romeoville, Illinois.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Karbon-X Corp., Axil Brands, Inc. or cbdMD, Inc., or pick any stock.

  • TickerSLSN on Nasdaq1
  • IndustryPerfumes, Cosmetics & Other Toilet Preparations1
  • HeadquartersRomeoville, Illinois1
  • Incorporated inDE2
  • Business address1319 Marquette Drive, Romeoville, Il 604462
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

25.9%Gross margin4
2.5%Operating margin4
2.9%Net margin4
18.6%Revenue growth, 20254
10.2%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Consumer Products brought in 88% of the revenue SOLESENCE, INC. broke down this way in fiscal 2025.

  1. Consumer Products$54.9M488%up 24% from 2024
  2. Personal Care ingredients$6.3M410%down 7% from 2024
  3. Advanced Materials$857.0K41%down 25% from 2024
  4. Product and Service, Other$270.0K40%down 41% from 2024
Products and services by year
Products and services20242025
Consumer Products$44.4M$54.9M
Personal Care ingredients$6.8M$6.3M
Advanced Materials$1.1M$857.0K
Product and Service, Other$457.0K$270.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue74¢$46.0M
  • Research and development7¢$4.1M
  • Selling, general and admin17¢$10.4M
  • Income tax0¢$73.0K
  • Profit3¢$1.8M

Out of $62.1M in revenue.4

Financial statements

Revenue567894$62.1M in 2025+396% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $12.5M$12.5M20192020: $17.1M$17.1M2020+37%2021: $29.5M$29.5M2021+72%2022: $37.3M$37.3M2022+27%2023: $37.3M$37.3M2023−0%2024: $52.3M$52.3M2024+40%2025: $62.1M$62.1M2025+19%
Gross profit567894$16.1M in 2025+514% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $2.6M$2.6M20192020: $6.0M$6.0M2020+129%2021: $8.7M$8.7M2021+45%2022: $8.4M$8.4M2022−4%2023: $7.8M$7.8M2023−6%2024: $16.2M$16.2M2024+107%2025: $16.1M$16.1M2025−1%
Operating income567894$1.6M in 2025
-$5.0M-$2.5M0$2.5M$5.0M$7.5M2019: -$2.8M-$2.8M20192020: $1.5M$1.5M20202021: $2.6M$2.6M2021+72%2022: -$2.3M-$2.3M20222023: -$3.5M-$3.5M2023+57%2024: $5.1M$5.1M20242025: $1.6M$1.6M2025−69%
Net income567894$1.8M in 2025
-$5.0M-$2.5M0$2.5M$5.0M2019: -$3.0M-$3.0M20192020: $989.0K$989.0K20202021: $2.3M$2.3M2021+135%2022: -$2.6M-$2.6M20222023: -$4.4M-$4.4M2023+67%2024: $4.2M$4.2M20242025: $1.8M$1.8M2025−58%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total revenue$62.1M$52.3M
Cost of revenue$46.0M$36.2M
Gross profit$16.1M$16.2M
Research and development expense$4.1M$3.8M
Selling, general and administrative expense$10.4M$7.2M
Net income from operations$1.6M$5.1M
Interest expense, net$931.0K$670.0K
Other income, net$1.2M
Net income before provision for income taxes$1.9M$4.5M
Provision for income taxes$73.0K$227.0K
Net income$1.8M$4.2M
Net income per share-basic$0.03$0.07
Weighted average number of basic common shares outstanding70.3M shares62.4M shares
Net income per share-diluted$0.02$0.07
Weighted average number of diluted common shares outstanding72.6M shares65.0M shares

Compare SOLESENCE, INC. with another company

Corporate structure

SOLESENCE, INC. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of SOLESENCE, INC.

  • Bradford T. Whitmore Filed SCHEDULE 13D/A on SOLESENCE, INC., latest Jun 2, 2025 (7 filings since Dec 23, 2021)
  • John Howard Conley Jr. Filed SC 13G/A on SOLESENCE, INC., latest Jan 14, 2022
  • SOLESENCE, INC. Romeoville, Illinois
    • Solésence, LLC Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SOLESENCE, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$38.0M4 Dec 31, 2025$35.5M4 Dec 31, 2024+7.0%
Accumulated depreciation$23.7M4 Dec 31, 2025$22.8M4 Dec 31, 2024+3.9%
Property and equipment, net$14.3M4 Dec 31, 2025$12.7M4 Dec 31, 2024+12.5%
Operating-lease assets (leased space)$6.9M4 Dec 31, 2025$7.9M4 Dec 31, 2024−12.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.3M4 Dec 31, 2025$1.4M4 Dec 31, 2024−8.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$18.5M4 Dec 31, 2025$20.3M4 Dec 31, 2024−8.7%
Raw materials$16.5M4 Dec 31, 2025$17.4M4 Dec 31, 2024−5.0%
Finished goods$4.7M4 Dec 31, 2025$4.9M4 Dec 31, 2024−3.3%

Properties, in its own words

As of the end of 2025 we operate two facilities in the Chicago suburbs - a 36,000 square-foot production, research and headquarters facility in Romeoville, Illinois and a 261,000 square-foot production and warehouse facility in Bolingbrook, Illinois. In late 2025 we consolidated our manufacturing operations in Burr Ridge, Illinois into our production facility in Bolingbrook.

The Romeoville facility houses our headquarters, advanced engineering, manufacturing (including particle coating, particle dispersion and pilot-scale manufacturing), and research and development with three applications development and formulating laboratories. The Romeoville facility has a quality control laboratory designed for the dual purposes of validating operations to cGMP and ISO standards and production process control. This laboratory is equipped to handle many routine analytical and in-process techniques that are currently required. All Romeoville manufacturing processes are registered under ISO 9001, ISO 22716 and ISO 14001, and we believe that the particle coating processes used for our ingredients and fully formulated sunscreens and cosmetic products for personal care are in compliance with the cGMP requirements of the FDA. The Romeoville site is registered with the FDA for API manufacturing, manufacturing, and packaging.

The rest of Item 2

The Bolingbrook facility houses our warehousing operations, sunscreen lotions manufacturing, dispersion manufacturing, filling and assembly of our consumer products and additional quality control spaces. The Bolingbrook facility is registered with the FDA for OTC drug manufacturing and packaging, with the site registered under ISO 9001, ISO 22716 and ISO 14001, and we believe that the particle coating processes used for our ingredients and fully formulated sunscreens and cosmetic products for personal care are in compliance with the cGMP requirements of the FDA. The Bolingbrook site is registered with the FDA for API manufacturing, manufacturing, and packaging.

We lease our Romeoville and Bolingbrook facilities. The Romeoville lease term was extended to January 31, 2028, in August 2024. During December 2021, we entered into a Standard Form Industrial Lease for a new facility in Bolingbrook, Illinois, amended May 12, 2025 which, among other things, will end in May of 2032, with options to extend this lease at market rent for each of three concurrent five-year periods.

With the addition of the Bolingbrook space in 2021, we believe that our leased facilities will provide sufficient capacity to fulfill current known customer demand as well as allow for the creation of substantial additional space to enable expansion of key production processes. We believe we will be able to expand certain operations, and consolidate others, to support additional growth in an economically efficient manner. We believe that our capital expenditures made in 2025, and projected for 2026, will support currently anticipated demand from existing and expected customers through 2026 and into 2027. Management continues to spend considerable time determining how best to optimize our facilities to maximize growth over the next few years. Our actual future capacity requirements will depend on many factors, including new and potential customer acceptance of our current and potential engineered materials, applications and products, both expected and currently unplanned growth from existing customers, continued progress in our research and development activities and product testing programs and the magnitude of these activities and programs.

Item 2 of the 10-K filed Mar 31, 2026.12

Leadership

Who has led SOLESENCE, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Joseph Cross2006–2008
  2. Jess Jankowski2008–now

President

  1. Joseph Cross2006–2008
  2. Jess Jankowski2010–now

Chief financial officer

  1. Jess Jankowski2006–2009
  2. Frank Cesario2009–2017
  3. Jaime Escobar2018
  4. Laura C. Riffner2025–now

Chief operating officer

  1. Kevin Cureton2020–now
2010201520202025
Board members and other officers (20)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Solésence, LLC Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • NANOPHASE TECHNOLOGIES CorpFeb 10, 2016 to Mar 31, 20252
  • NANOPHASE TECHNOLOGIES CORPORATIONOct 1, 1997 to Feb 1, 20162

Timeline

  1. Oct 5, 20268-K Entered a material agreement39
  2. Oct 2, 20268-K Listing notice or transfer40
  3. Aug 21, 20268-K Earlier financial statements no longer reliable41
  4. Aug 20, 20268-K Results of operations42
  5. Jul 10, 20268-K Entered a material agreement43
  6. May 12, 20268-K Results of operations44
  7. Apr 29, 20268-K Executive or director change45
  8. Mar 31, 20268-K Results of operations46
  9. Dec 3, 20258-K Executive or director change47
  10. Dec 1, 20258-K Entered a material agreement; Executive or director change48
  11. Nov 13, 20258-K Results of operations49
  12. Nov 6, 20258-K Entered a material agreement50
  13. Sep 23, 2008New chief executive Jess Jankowski becomes CEO13
  14. Sep 29, 2006New chief executive Joseph Cross becomes CEO14

Calendar

Coming up

  1. Nov 10, 2026Reports results for the quarter ending Sep/202651

When it reported results

  1. Aug 20, 2026Reported quarterly or annual results42
  2. May 12, 2026Reported quarterly or annual results44
  3. Mar 31, 2026Reported quarterly or annual results46
  4. Nov 13, 2025Reported quarterly or annual results49
  5. Jul 31, 2025Reported quarterly or annual results52
  6. May 7, 2025Reported quarterly or annual results53
  7. Mar 26, 2025Reported quarterly or annual results54
  8. Oct 30, 2024Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

187 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 43 major events, 95 insider forms, 8 large holders, 20 other. The latest 20:

  1. Oct 5, 20268-K EDGAR
  2. Oct 2, 20268-K EDGAR
  3. Aug 21, 20268-K EDGAR
  4. Aug 20, 20268-K EDGAR
  5. Aug 19, 202610-Q QUARTERLY REPORT EDGAR
  6. Aug 14, 2026NT 10-Q EDGAR
  7. Jul 10, 20268-K EDGAR
  8. May 12, 202610-Q QUARTERLY REPORT EDGAR
  9. May 12, 20268-K EDGAR
  10. Apr 29, 20268-K EDGAR
  11. Apr 23, 202610-K/A AMENDMENT TO FORM 10-K EDGAR
  12. Mar 31, 202610-K ANNUAL REPORT EDGAR
  13. Mar 31, 20268-K EDGAR
  14. Dec 30, 20254 EDGAR
  15. Dec 11, 20254 EDGAR
  16. Dec 3, 20258-K EDGAR
  17. Dec 1, 20258-K EDGAR
  18. Nov 13, 20258-K EDGAR
  19. Nov 12, 202510-Q QUARTERLY REPORT EDGAR
  20. Nov 6, 20258-K CURRENT REPORT EDGAR

The 187 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

127 open-market trades by officers, directors and large owners since October 2021: 73 buys and 54 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 24, 2025WHITMORE R JANETDirectorBuy2,500$1.91$4.8KForm 4
Nov 19, 2025WHITMORE R JANETDirectorBuy10,000$1.92$19.2KForm 4
Nov 18, 2025WHITMORE R JANETDirectorBuy267$1.83$489Form 4
Nov 17, 2025WHITMORE R JANETDirectorBuy5,000$1.87$9.3KForm 4
Nov 14, 2025WHITMORE R JANETDirectorBuy19,789$1.73$34.2KForm 4
Jun 6, 2025Cureton KevinChief Operating OfficerSale38,807$3.80$147.5KForm 4
Jun 5, 2025Cureton KevinChief Operating OfficerSale4,693$3.96$18.6KForm 4
May 29, 2025WHITMORE BRADFORD T10% ownerBuy6,689,000$4.20$28.1MForm 4
May 29, 2025WHITMORE BRADFORD T10% ownerSale6,689,000$4.20$28.1MForm 4
Oct 29, 2024WHITMORE R JANETDirectorBuy45,333$0.84$37.9KForm 4
Sep 24, 2024WHITMORE R JANETDirectorBuy23,900$1.60$38.2KForm 4
Sep 23, 2024Cureton KevinChief Operating OfficerBuy4,716$1.48$7.0KForm 4
Sep 23, 2024WHITMORE R JANETDirectorBuy26,000$1.59$41.3KForm 4
Sep 19, 2024WHITMORE R JANETDirectorBuy2,200$1.56$3.4KForm 4
Sep 9, 2024WHITMORE R JANETDirectorBuy4,488$1.51$6.8KForm 4
Sep 4, 2024WHITMORE R JANETDirectorBuy9,019$1.50$13.5KForm 4
Sep 3, 2024WHITMORE R JANETDirectorBuy244$1.48$360Form 4
Aug 27, 2024WHITMORE R JANETDirectorBuy1,177$1.52$1.8KForm 4
Aug 22, 2024WHITMORE R JANETDirectorBuy15,922$1.60$25.4KForm 4
Aug 21, 2024WHITMORE R JANETDirectorBuy5,118$1.57$8.0KForm 4

All 127 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Bradford T. WhitmoreSCHEDULE 13D/A, 7 filings Dec 23, 2021 to Jun 2, 202556
  • John Howard Conley Jr.SC 13G/A, 1 filing Jan 14, 202257

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Jess Jankowski60$357.1K$565.3K58
2024Kevin Cureton64$309.3K$481.3K58
2023Chief Executive Officer$341.4K$374.8K58
2023Chief Operating Officer$294.5K$322.7K58

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 45. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC830,508$610.4K0.0%+18,797
BlackRock, Inc.463,652$340.8K0.0%−605,097
Bank of New York Mellon Corp317,609$233.4K0.0%+273,536
Millennium Management LLC276,497$203.2K0.0%New
Geode Capital Management, LLC238,514$175.4K0.0%−213,015
Morgan Stanley188,797$138.8K0.0%−5,985
Donaldson Capital Management, LLC150,000$110.2K0.0%New
Susquehanna International Group, Llp111,340$81.8K0.0%+97,382
Vanguard Fiduciary Trust Co106,692$78.4K0.0%−16,314
Jane Street Group, LLC99,385$73.0K0.0%New
Goldman Sachs Group Inc92,804$68.2K0.0%+65,180
Tower Research Capital LLC (TRC)55,275$40.6K0.0%+43,348
Zacks Investment Management37,955$27.9K0.0%No change
Northern Trust Corp36,932$27.1K0.0%−100,583
Aqr Capital Management LLC24,702$18.2K0.0%New
Qube Research & Technologies Ltd22,038$16.2K0.0%New
Wealth Enhancement Advisory Services, LLC22,758$15.4K0.0%+478
Pathstone Holdings, LLC20,000$14.7K0.0%No change
Barclays PLC19,807$14.6K0.0%−3,775
State Street Corp18,150$13.3K0.0%−390,837
Citigroup Inc5,695$4.2K0.0%+4,709
Royal Bank Of Canada4,558$3.0K0.0%+849
Bnp Paribas Financial Markets1,643$1.2K0.0%−3,959
Wells Fargo & Company/mn1,588$1.2K0.0%−5,442
Russell Investments Group, Ltd.1,401$1.0K0.0%−457

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How SOLESENCE, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSOLESENCE, INC.1
  • CIK0000883107
  • Employer ID (EIN)36-368786312
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company12
  • Incorporated inDelaware12
  • Fiscal year endsDecember 311
  • Industry code (SIC)2844 Perfumes, Cosmetics & Other Toilet Preparations1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1319 Marquette Drive, Romeoville, IL 604461
  • Phone63077160781
  • Shares outstanding70,647,045 as of Aug 19, 202611
  • Public float$27.3M as of Jun 30, 202512
  • AuditorRSM US LLP, Milwaukee, Wisconsin PCAOB ID 49; no auditor attestation of internal control over financial reporting12
  • On EDGAR sinceMar 13, 19971
  • Filings1,235 in all: 4 (647), 8-K (212), 10-Q (86), DEF 14A (29), SC 13G/A (28), 10-K (26), SC 13D/A (21), 3 (14)1
    All 42 form types

    SC 13G (14), UPLOAD (14), 4/A (11), DEFA14A (11), CORRESP (10), CT ORDER (9), 10-K/A (8), 5 (8), S-3/A (8), 10-Q/A (6), EFFECT (6), PRE 14A (6), S-1/A (6), S-3 (6), S-8 (6), 8-K/A (5), REGDEX (4), S-1 (4), 10-K405 (3), 8-A12G (3), NT 10-Q (3), RW (3), SD (3), 3/A (2), 424B3 (2), D (2), SC 13D (2), 25 (1), 424B2 (1), 8-A12B (1), CERT (1), NT 10-K (1), POS AM (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 19, 2026
    Proxy statement (DEF 14A) Jul 30, 2025
    Latest 8-K (8-K) Oct 5, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par value per shareSLSNNASDAQ

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).12

Risk factors and legal proceedings

Legal proceedings

As previously disclosed, on October 31, 2025, we entered into a Confidential Settlement Agreement and Release (the “Settlement Agreement”) with Solarium Brands, LLC and A-Frame Brands, LLC (collectively, “Solarium”). Pursuant to the Settlement Agreement, we and Solarium agreed to settle and compromise disputes arising from certain consumer personal care products that we previously manufactured for and sold to Solarium. As part of the Settlement Agreement, Solarium agreed to pay us a one-time settlement payment of $675,000 on or before January 15, 2026, which payment was made in December 2025

The opening of Item 3, Legal Proceedings.12

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58